Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Servi...(er encounter forms to capture infusion c...),Health

Date:2/13/2008

er encounter forms to capture infusion charges. Not only were the visits themselves complex, requiring multiple therapies and involving multiple nurses, but the overhead to redesign encounter forms, retrain nurses and monitor compliance resulting from annual regulatory changes was extremely high. Now that we have technology in place to support the charge capture process and automate updates related to annual changes, our nurses are able to focus more on the care of the patient and less on administrative demands," said Lori Buswell, RN, MS, CS, OCN, director, nursing patient care services/clinical operations and decision support, Dana-Farber Cancer Institute. She further added that throughout the phased in roll-out, during the first week of usage, more than 95 percent of captured charges were ready for export by the following morning, greatly reducing charge lag.

The Infusion Services Module was fully deployed to Dana-Farber's 120 infusion nurses across its Boston locations in less than 90 days. Completion of this deployment means that MedAptus technology is now used for point-of- care charge capture related to Dana-Farber's nearly 200,000 annual outpatient visits, roughly 90,000 of which include infusions.

"We are honored to have worked so closely with Dana-Farber on a solution that effectively eliminates the regulatory headaches that have increasingly burdened clinical staff involved in the delivery of infusion services. And of tremendous organizational benefit are the revenue capture rules which provide real-time feedback at the point-of-care to ensure accurate and complete capture of services, medications and supplies," said David Delaney, MD, chief medical officer of MedAptus. "Dana-Farber was an excellent development partner, providing tremendous input around our Infusion product's functionality. We applaud their keen insights and their ability to rapidly - and successfully - implement new technologies."

About MedAptus Corporation

Me
'/>"/>

SOURCE MedAptus Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
2. Kidney Cancer Drug Linked to Higher Rate of Heart Problems
3. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
4. HPV-positive head and neck cancer patients fare better than HPV-negative patients
5. DCIS patients overestimate breast cancer risks
6. Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks
7. HPV-Positive Head and Neck Cancers Fare Better
8. Precancerous Breast Lesions Cause Unnecessary Worry
9. New Jefferson trial to test radiation-emitting beads against advanced liver cancer
10. Yale test detects early stage ovarian cancer with 99 percent accuracy
11. Chicago Tribune Does Story on Canine Cancer, Morris Animal Foundation (MAF) Effort to Find a Cure - MAF Can Provide Information - Local Angles for a Feature Story